Clinical Trials Logo

Pulmonary Arterial Hypertension clinical trials

View clinical trials related to Pulmonary Arterial Hypertension.

Filter by:

NCT ID: NCT03884465 Not yet recruiting - Clinical trials for Pulmonary Arterial Hypertension

Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil

Start date: May 30, 2019
Phase: Phase 2
Study type: Interventional

Acute and chronic hemodynamic dose-response and safety evaluation of LIQ861 in PAH subjects.

NCT ID: NCT03863990 Not yet recruiting - Clinical trials for Pulmonary Arterial Hypertension

Study Performed at Various Medical Centers to Learn More About Survival and Expected Course of Pulmonary Arterial Hypertension, a Type of High Blood Pressure in the Lungs Related to the Narrowing of the Small Blood Vessels in the Lungs

START
Start date: March 7, 2019
Phase:
Study type: Observational

In this study researchers want to learn more about Pulmonary Arterial Hypertension, a type of high blood pressure in the lungs related to the narrowing of the small blood vessels in the lungs (group 1 according to WHO classification). Goal of the study is to describe the signs and risk factors of the illness at study start and the chances of survival.

NCT ID: NCT03841344 Active, not recruiting - Clinical trials for Pulmonary Arterial Hypertension

Repeatability and Sensitivity to Change of Non-invasive Endpoints in PAH

RESPIRE
Start date: September 15, 2015
Phase: N/A
Study type: Interventional

Pulmonary arterial hypertension (PAH) is progressive life limiting disease with a median survival of less than 3 years without treatment. Current drug trials in PAH commonly use simple tests for example the 6-minute walk test, blood tests such as N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and BNP, and haemodynamic measures such as PAP and PVR obtained by RHC as endpoints. These tests are surrogate markers of disease severity in patients with pulmonary hypertension. There is now evidence suggesting that magnetic resonance imaging (MRI) may be helpful in the follow up of patients with PAH with high accuracy for the detection of treatment failure, this is because MRI can track changes occurring in the heart by direct visualisation of cardiopulmonary morphology and function, an advantage over existing methods. However, the reproducible of MRI measurements in patients with PAH is not known, and the comparative repeatability of MRI in relation to traditional candidate endpoints such as walk tests and blood tests used in drug trials is not known.

NCT ID: NCT03838445 Not yet recruiting - Clinical trials for Pulmonary Arterial Hypertension

Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)

RELIEVE-PAH
Start date: March 1, 2019
Phase: N/A
Study type: Interventional

The objectives of the RELIEVE-PAH study are to obtain first-in-human experience with the study device in patients with severe pulmonary arterial hypertension, including evidence of initial safety, device performance and possible signals of clinical effectiveness.

NCT ID: NCT03833323 Not yet recruiting - Clinical trials for Pulmonary Arterial Hypertension

Implantable System for Remodulin Post-Approval Study

ISR PAS
Start date: March 15, 2019
Phase:
Study type: Observational

The purpose of the Implantable System for Remodulin (ISR) Post Approval Study (PAS) is to provide evaluation and periodic reporting of the safety and effectiveness of Medtronic market-released ISR, including the catheter and the pump.

NCT ID: NCT03819777 Recruiting - Clinical trials for Pulmonary Arterial Hypertension

Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH)

VOC-PAH
Start date: March 1, 2018
Phase:
Study type: Observational

Aim: to investigate the role of inflammation and auto-immunity in pulmonary arterial hypertension by using the profile of volatile organic compounds. Hypothesis: first, the investigators hypothesize that at time of diagnosis the VOC profiles will discriminate patients with PAH-CTD and idiopathic PAH (IPAH) from patients with systemic sclerosis or systemic lupus erythematosus (CTD) without PAH, supporting the contention that there is a overlapping inflammatory and auto-immune pathway in PAH. During follow-up, the investigators will measure the VOC profiles of patients in all three groups who will be treated according standard clinical care. The hypothesis is that VOC profiles are affected by therapy.

NCT ID: NCT03810443 Not yet recruiting - Clinical trials for Pulmonary Arterial Hypertension

Prevalence of the Hyperventilation Syndrome in Pulmonary Arterial Hypertension

HYPER2
Start date: January 14, 2019
Phase: N/A
Study type: Interventional

Dyspnea is a major symptom in pulmonary arterial hypertension and people with the same haemodynamic have generally different degree of dyspnea in pulmonary arterial hypertension. The hyperventilation syndrome is a frequent cause of dyspnea in general population and in respiratory diseases like asthma but has never been studied in pulmonary hypertension. The goal of this study is to measure the prevalence of pulmonary hypertension in a population of patients with controlled pulmonary arterial hypertension (PAH).

NCT ID: NCT03795428 Not yet recruiting - Clinical trials for Pulmonary Arterial Hypertension

Long-Term Extension Study of PB1046 in PAH Subjects Having Completed Studies PB1046-PT-CL-0004 or PB1046-PT-CL-0005

LTE
Start date: April 6, 2019
Phase: Phase 2
Study type: Interventional

This is a multi-center, Phase 2 Long-Term Extension Study to assess the safety, tolerability, and efficacy of PB1046 at an optimally titrated dose. This is a Long-Term Extension Study for subjects with pulmonary arterial hypertension (PAH), having participated in double-blind Study PB1046-PT-CL-0004 or open-label Study PB1046-PT-CL-0005. The study will include adult subjects previously diagnosed with symptomatic PAH, who are receiving background clinician-directed therapy for PAH. All subjects during the Long-Term Dosing and Safety Follow-Up Period, will continue to be followed for safety and tolerability, as well as for periodic efficacy, quality of life data and immunogenicity. The study will continue until such time when PB1046 becomes commercially available to the subject or the Sponsor terminates the study due to lack of efficacy, safety or other reasons.

NCT ID: NCT03789643 Not yet recruiting - Clinical trials for Pulmonary Arterial Hypertension

Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension

RELIEF-PAH
Start date: March 2019
Phase: Phase 2
Study type: Interventional

Study to evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-251 administered for 24 weeks in participants with pulmonary arterial hypertension (PAH)

NCT ID: NCT03782818 Not yet recruiting - Clinical trials for Pulmonary Arterial Hypertension

Olaparib for PAH: a Multicenter Clinical Trial

OPTION
Start date: March 15, 2019
Phase: Phase 1
Study type: Interventional

The main OBJECTIVE of this proposal is to extend our preclinical findings on the role of DNA damage and poly(ADP-ribose) polymerases (PARP) inhibition as a therapy for a devastating disease, pulmonary arterial hypertension (PAH), to early-phase clinical trials. We, and others, have published strong evidence that DNA damage accounts for disease progression in PAH and showed that PARP1 inhibition can reverse PAH in several animal models1. Interestingly, PARP1 inhibition is also cardioprotective. Olaparib, an orally available PARP1 inhibitor, can reverse cancer growth in animals and humans with a good safety profile, and is now approved for the treatment of ovarian cancer in Canada, Europe and the USA. The time is thus right to translate our findings in human PAH. The primary objective of this Phase 1B study is to confirm the safety of using olaparib in PAH patients, and precise the sample size of a future Phase 2 trial. In addition to safety, efficacy signals will thus be assessed.